glp 1 and biologics DNA-based delivery of incretin receptor agonists using MYO Technology leads to durable weight loss in a diet-induced obesity model Using GLP-1 Agonists with Biologics
Description
The increased sympathetic tone may explain a known GLP-1RA class effect of a modest but significant increase in heart rate, the clinical consequences of which are undetermined
These processes are examined in terms of receptor activation and intracellular biochemical responses rather than outcome-based effects
What is a GLP- 1 Agonist and how do they work
Artificial Intelligence in Anti-Obesity Drug Discovery: Unlocking Next-Generation Therapeutics
[46] Enebo, L
